作者丨彭鑫 编辑丨安安 2月6日，欣旺达发布公告称，欣旺达的子公司欣旺达动力科技股份有限公司与吉利系公司威睿电动汽车 技术（宁波）有限公司在一审阶段达成和解，后者将在《和解协议》生效后撤回起诉。双方同意对于更 换动力电池包相关的费用按照实际成本进行认定，根据实际发生金额经双方核对后确认，双方商定按比 例分担该实际发生金额，同时，事件处理后的相关电池包全部归欣旺达所有。欣旺达预计，本次事件对 上市公司2025年归母净利润的影响为5亿~8亿元。 ...

作者丨彭鑫 编辑丨安安 2月6日，理想汽车董事长兼CEO李想称，将推出全新一代理想L9 Livis版，售价55.98万元。 全新一代理想L9Livis版搭载2颗理想汽车全自研的"马赫100"芯片，拥有全球最强的2560TOPS算力；全球首次在60万以内搭载800V全主动悬架系统；搭载首 个"完全体"全线控底盘，集成线控转向、四轮转向、全电控机械制动(EMB)三项关键技术。 其中，"马赫100"芯片是理想汽车自2022年起自研的核心技术，配合理想汽车自研大模型和自研操作系统，全新一代理想L9的智能化程度将大幅提升。 ...

Group 1 - The Ministry of Commerce and nine other units encourage local governments to increase the number of subsidies for replacing old consumer goods during the Spring Festival, aiming to boost offline retail support and create a vibrant atmosphere for new purchases [1] Group 2 - Dongyi Risheng plans to acquire 100% equity of Zhongcheng Daye for RMB 1 million and will subsequently increase Zhongcheng Daye's registered capital from RMB 10 million to RMB 50 million, focusing on construction labor subcontracting and interior decoration [2] Group 3 - Dayasengxiang's aluminum plate and strip project has made significant progress with the trial operation of production lines and completion of cold rolling machine debugging, establishing a coherent production capability from casting to cold rolling [3] Group 4 - Weixing New Materials has completed the acquisition of an 88.2557% stake in Beijing Songtiancheng Technology Co., Ltd. for approximately RMB 111 million, enhancing its product chain in municipal pipeline sectors [4] Group 5 - Zhongyuan Home announced the early termination of a rental agreement with Mingchuang Furniture, resulting in a rental amount of RMB 1.0226 million being settled, which does not require board approval [5] Group 6 - Ecovacs has established a wholly-owned artificial intelligence technology company in Shanghai with a registered capital of RMB 10 million, focusing on AI application software development and IoT technology services [6]

福达合金公告称，2026年2月6日公司第七届董事会第二十二次会议审议通过议案，拟向中国银行间市场 交易商协会申请注册发行科技创新债券。注册总额不超5亿元，期限不超10年，利率根据市场等情况确 定，发行对象为全国银行间债券市场机构投资者。募集资金扣除发行费用后，用于企业生产经营等。本 次发行事宜尚需公司股东会审议，以及获交易商协会批准。若发行成功，将拓宽融资渠道、降低成本， 支持战略发展。 ...

郎酒庄园会员数量方面，2025年会员发展数量同比增长44%；开瓶数量方面，总开瓶数同比增长18%（未包含光瓶酒 数据，青花郎指第五代青花郎开瓶数）； 此外，公司逐步完成青花郎、红花郎·15、红花郎·10、郎牌郎产品的市场迭代，完成龙马郎上市。 2月5日，郎酒股份官方公众号发布一月份销售出货创新高的消息。当中披露，汪博炜总经理表示，2026年1月以来， 随着郎酒品牌年会的召开和近500场渠道伙伴新春联谊会推进，郎酒x伙伴x客户合力拼出了1月份出货创历史新高、单 日最高出货2.7亿元的开门红。 在回顾2025年成果时，郎酒方面提到，全年经销商出货量在2024年基础上实现微增长；商家数量、终端门店、宴席数 量、郎酒庄园会员数量与开瓶数量等实现量质齐升。 商家数量2025年进一步推进全国化，商家数量增加800+；终端门店2025年联盟商共拓展增加近10万家；宴席数量方 面，红花郎宴席同比增长73%，兼香宴席同比增长48%。 （企业官方公众号） ...

（企业公告） 2月5日，牧原股份发布公告称，2026年1月份，公司销售商品猪700.9万头，同比变动2.73%（其中向全资子公司牧原肉 食品有限公司及其子公司合计销售商品猪311.6万头）；商品猪销售均价12.57元/公斤，同比变动-16.92%。商品猪销售 收入105.66亿元，同比变动-11.93%。 ...

（云顶新耀公告） 2月6日，云顶新耀发布公告称，其新药维适平®（精氨酸艾曲莫德片）在中国获得新药上市申请批准，用于治疗对传 统治疗或生物制剂应答不充分的中度至重度活动性溃疡性结肠炎成人患者。 公司将积极筹备维适平®的商业化上市，努力将该疗法尽快带给国内患者，并推动纳入国家医保目录。此次获批是公 司2030年发展战略的重要组成部分，战略明确提出以"BD合作+自研"双轮驱动，实现商业化和研发的双重价值。公司 计划到2028年实现收入规模超过100亿元人民币，到2030年超过150亿元人民币，收入年复合增长率预计在2025至2030 年超过50%。 此次批准基于亚洲多中心III期注册临床ENLIGHTUC研究及全球III期注册研究ELEVATEUC的结果，ENLIGHTUC研究 纳入340名患者，在治疗中达到了统计学显著性和良好的安全性特征。 ...

Group 1 - Dongpeng Beverage listed on the Hong Kong Stock Exchange on February 3, 2026, with projected revenue for 2025 expected to be between 20.76 billion to 21.12 billion yuan, representing a year-on-year growth of 31.07% to 33.34% [1] - The company anticipates a net profit attributable to shareholders of 4.34 billion to 4.59 billion yuan, with a year-on-year increase of 30.46% to 37.97% [1] - The expected growth in net profit excluding non-recurring items is projected to be between 26.29% to 33.34% [1] Group 2 - Gaoxin Retail announced that it is currently unable to contact CEO Li Weiping, and the management responsibilities are being overseen by Chairman Hua Yunen [2] - The company confirmed that its operations are proceeding normally, with no impact on the supply of goods or services during the peak sales season [2] Group 3 - Chongqing Beer reported a revenue of 14.722 billion yuan for 2025, a year-on-year increase of 0.53%, and a net profit of 1.231 billion yuan, up 10.43% [3] - The company launched over 30 new products in 2025, including tea beer and fruit-flavored soda, to enhance its product offerings [3] - The company’s strategic initiatives included optimizing product structure and expanding into non-traditional beverage channels, contributing to a resilient business performance [3] Group 4 - Liangpinpuzi announced that its controlling shareholder, Ningbo Hanyi, received execution notices due to overdue debts totaling approximately 280 million yuan [4] - The company stated that the operational impact from this situation is currently minimal, and business activities are proceeding as normal [4] Group 5 - Yum China reported a 4% increase in total revenue to 11.8 billion USD for the fiscal year 2025, with a 9% increase in Q4 revenue to 2.8 billion USD [6] - The company opened 1,706 new stores in 2025, bringing the total to 18,101, with a focus on expanding its KPRO brand [6] - KPRO, which offers healthy food options, has seen significant sales growth, contributing to double-digit sales increases for the parent brand [6] Group 6 - Dabeinong announced the passing of its actual controller and chairman, Shao Genhuo, on February 3, 2026, with Vice Chairman Zhang Lizhong taking over the chairman's responsibilities [7] - The company confirmed that its board and management are functioning normally, and business operations continue without disruption [7] Group 7 - Sam's Club former executive Andrew Miles has joined Metro China as an advisor, effective February 2026, to enhance product competitiveness and long-term user value [8] Group 8 - Langjiu reported record high sales in January 2026, with a single-day sales peak of 270 million yuan [9] - The company noted a slight increase in distributor shipments and significant growth in membership and product launches throughout 2025 [9] Group 9 - Jinshiyuan expressed cautious optimism for the upcoming Spring Festival sales, indicating that while achieving internal expectations is possible, overall performance may decline compared to the previous year [10][11] - The company is actively preparing for the holiday season and managing inventory to balance supply and demand [11]

Group 1 - Aier Eye Hospital clarified that it has no direct equity or operational management relationship with Xiangyang Hengtai Kang Hospital, which is a joint venture established by Aier Medical Investment Group and other investors [1] - Aier Medical Investment does not participate in the daily operations of Xiangyang Hengtai Kang Hospital, and there is no equity control or business relationship with Hunan Hengtai Kang Rehabilitation Medical Industry Development Co., Ltd [1] Group 2 - Eli Lilly reported a total revenue of $65.179 billion for 2025, a 45% year-on-year increase, with its star product, Tirzepatide, generating $36.507 billion in sales [2] - The company provided guidance for 2026, expecting revenue to reach between $80 billion and $83 billion, with non-GAAP EPS projected between $33.50 and $35.00 [2] Group 3 - Novo Nordisk's revenue for 2025 is projected to grow by 6% to 309.1 billion Danish Krone, with a 10% increase at fixed exchange rates [3] - Sales in the Greater China region for rare diseases grew by 84% year-on-year at fixed exchange rates, driven by sales in rare blood diseases [3] - The company plans to propose a dividend of 7.95 Danish Krone per share for 2025, totaling 11.70 Danish Krone for the year, and has initiated a stock buyback program of up to 15 billion Danish Krone [3] Group 4 - Innovent Biologics achieved total product revenue of approximately 11.9 billion Yuan in 2025, a year-on-year increase of about 45% [4] - The company expanded its oncology product portfolio to 13 products, with core products like Tyvyt (sintilimab injection) showing steady growth [4] - The company successfully entered the chronic disease commercialization field, with key products contributing significantly to revenue growth [5] Group 5 - Sequoia China completed the global acquisition of moxifloxacin business, establishing Hangzhou Sequoia Biopharmaceutical Co., Ltd, with former Pfizer executive Jin Xiaodong appointed as CEO [6] - The acquisition includes specific assets related to moxifloxacin, ensuring a solid foundation for the product's continued supply and future development [6] Group 6 - Jiashitang announced a change in its controlling shareholder to Tongrentang Group, following a share transfer agreement with Everbright Industrial and Everbright Health [7] - The transfer involves significant shareholdings, leading to a change in the actual controller to the State-owned Assets Supervision and Administration Commission of Beijing [7]

Core Insights - The company reported a 6% increase in net sales for Q2 of FY2026, reaching $4.229 billion, with organic net sales growing by 4% [1] - The company achieved a net profit of $162 million, reversing previous losses [1] - Adjusted gross margin increased by 40 basis points to 76.5%, driven by the Profit Recovery and Growth Plan (PRGP) [1] Financial Performance - Operating profit margin improved significantly to 9.5% from -14.5% year-over-year, with adjusted operating margin expanding by 290 basis points to 14.4% [1] - The PRGP contributed to operational efficiency, including competitive procurement strategies and reduced excess inventory [1] Market Performance - In the China mainland market, organic net sales grew by 13%, marking the second consecutive quarter of double-digit growth, attributed to product innovation and increased consumer investment [2] - The company experienced market share growth across all categories in the high-end beauty market, with notable performance from brands like La Mer, TOM FORD, and Le Labo [3] Future Outlook - The company raised its full-year guidance for FY2026, expecting organic net sales growth of 1% to 3% and adjusted operating margin between 9.8% and 10.2% [3] - The CEO emphasized the success of the "Reinventing Beauty" strategy, which has revitalized the business and led to significant operational and cultural transformation [4]